Literature DB >> 7492095

Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.

J V Martinez-Suarez1, J L Rodriguez-Tudela.   

Abstract

Two groups of recent clinical isolates of Candida albicans consisting of 101 isolates for which fluconazole MICs were < or = 0.5 microgram/ml (n = 50) and > or = 4.0 micrograms/ml (n = 51), respectively, were compared for their susceptibilities to fluconazole, clotrimazole, miconazole, ketoconazole, and itraconazole. Susceptibility tests were performed by a photometer-read broth microdilution method with an improved RPMI 1640 medium supplemented with 18 g of glucose per liter (RPMI-2% glucose; J. L. Rodríguez-Tudela and J. V. Martínez-Suárez, Antimicrob. Agents Chemother. 38:45-48, 1994). Preparation of drugs, basal medium, and inocula was done by the recommendations of the National Committee for Clinical Laboratory Standards. The MIC endpoint was calculated objectively from the turbidimetric data read at 24 h as the lowest drug concentration at which growth was just equal to or less than 20% of that in the positive control well (MIC 80%). In vitro susceptibility testing separated azole-susceptible strains from the strains with decreased susceptibilities to azoles if wide ranges of concentrations (20 doubling dilutions) were used for ketoconazole, miconazole, and clotrimazole. By comparison with isolates for which fluconazole MICs were < or = 0.5 microgram/ml, those isolates for which fluconazole MICs were > or = 4.0 micrograms/ml were in general less susceptible to other azole drugs, but different patterns of decreased susceptibility were found, including uniform increases in the MICs of all azole derivatives, higher MICs of several azoles but not others, and elevated MICs of fluconazole only. On the other hand, decreased susceptibility to any other azole drug was never found among strains for which MICs of fluconazole were lower.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492095      PMCID: PMC162772          DOI: 10.1128/AAC.39.7.1512

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods.

Authors:  J N Galgiani; J Reiser; C Brass; A Espinel-Ingroff; M A Gordon; T M Kerkering
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 2.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 3.  Mechanisms and clinical impact of antifungal drug resistance.

Authors:  H Vanden Bossche; D W Warnock; B Dupont; D Kerridge; S Sen Gupta; L Improvisi; P Marichal; F C Odds; F Provost; O Ronin
Journal:  J Med Vet Mycol       Date:  1994

4.  Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use.

Authors:  E Lefler; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  Azole resistance in Candida albicans.

Authors:  J F Ryley; R G Wilson; K J Barrett-Bee
Journal:  Sabouraudia       Date:  1984

6.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

7.  In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

Authors:  F Barchiesi; A L Colombo; D A McGough; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.

Authors:  J N Galgiani; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

9.  pH and other effects on the antifungal activity of cilofungin (LY121019).

Authors:  K A McIntyre; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

10.  Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.

Authors:  C E Hughes; R L Bennett; I C Tuna; W H Beggs
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

View more
  14 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Genetic dissimilarity of two fluconazole-resistant Candida albicans strains causing meningitis and oral candidiasis in the same AIDS patient.

Authors:  J Berenguer; T M Diaz-Guerra; B Ruiz-Diez; J C Bernaldo de Quiros; J L Rodriguez-Tudela; J V Martinez-Suarez
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

3.  Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.

Authors:  D Law; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

4.  Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test.

Authors:  J L Rodríguez-Tudela; J V Martinez-Suarez
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates.

Authors:  J V Martinez-Suarez; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

7.  Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans.

Authors:  J L Rodríguez-Tudela; J Berenguer; J V Martínez-Suárez; R Sanchez
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

8.  Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi.

Authors:  E Herreros; C M Martinez; M J Almela; M S Marriott; F G De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  In vitro comparison of activities of terbinafine and itraconazole against Paracoccidioides brasiliensis.

Authors:  R C Hahn; C J F Fontes; R D Batista; J S Hamdan
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

10.  Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients.

Authors:  F Dronda; M Alonso-Sanz; F Laguna; F Chaves; J V Martínez-Suárez; J L Rodríguez-Tudela; A González-López; E Valencia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.